4. Unpublished data from the ADCS trials (total scores, provided via personal communication).
| Measurement | Baseline | 6 months' follow‐up | 18 months' follow‐up | Linear mixed‐effects model at 18 months | |||
| Placebo mean (SD) | Omega‐3 PUFA mean (SD) |
Placebo mean (SD) |
Omega‐3 PUFA mean (SD) |
Placebo mean (SD) |
Omega‐3 PUFA mean (SD) |
||
| ADAS‐Coga | 23.96 (9.21) n = 162 |
23.77 (8.87) n = 236 |
26.73
(10.7) n = 148 |
26.53
(11.07) n = 217 |
31.53 (14.57) n = 128 | 31.17
(14.76) n = 175 |
‐ |
| ADCS‐ADL | 59.68 (12.9) n= 164 |
60.12 (12.32) n = 238 |
56.8
(15.43) n = 147 |
55.55
(14.94) n = 219 |
‐ | ‐ | ‐ |
| CDR‐SOB | 5.77
(2.61) n = 164 |
5.61 (2.62) n = 238 |
6.75
(3.16) n = 148 |
6.86
(3.3) n = 216 |
‐ | ‐ | ‐ |
| NPI | 9.15 (10.83) n = 164 |
8.92 (10.37) n = 238 |
9.58 (10.8) n = 146 |
11.17 (12.47) n = 219 |
‐ | ‐ | ‐ |
| QoL‐AD informant rated | 36.96 (6.13) n = 151 |
36.45 (5.78) n = 220 |
36.31 (5.82) n = 136 |
34.55 (5.84) n = 195 |
34.91 (6.3) n = 120 |
33.42 (5.95) n = 162 |
P value = 0.41 |
| QoL‐AD participant rated | 40.43 (5.38) n = 150 |
40.0 (4.84) n = 222 |
39.86 (5.41) n = 133 |
39.76 (5.33) n = 199 |
40.02 (6.09) n = 119 |
39.63 (5.45) n = 150 |
P value = 0.66 |
ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; CDR‐SOB: Clinical Dementia Rating ‐ Sum of Boxes; n: number of participants; NPI: Neuropsychiatric Inventory; PUFA: polyunsaturated fatty acid; QoL‐AD: Quality of Life Alzheimer's Disease; SD: standard deviation.
aFor ADAS‐Cog missing items imputed with last observation carried forward; missing total scores not imputed.